Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1907 : TKKK  update : 2024/09/30
CommentHuman cell line derived from intrahepatic bile duct cancer. TKG0456 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Katayose, Y.
Year of deposit 2004
Original cell TKG0456
Animal _human < Mammals
Genus Homo
Species sapiens
Tissue Intrahepatic bile duct
Disease name intraohepatic bile duct carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0456)
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_5599
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method (0.05% Trypsin + 0.02% EDTA) or (0.25% Trypsin + 0.04% EDTA)
Coating dish type I collagen coated dish
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/4 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
STR(human) OK
Images
deposit info
lot info
Reference information Reference 0
User's Publication 25


To topTop
Reference

To topTop
User's Publication
21829  Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N.  Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.  Science  2024  385(6705):eadl6173  PubMed ID: 38991060   DOI: 10.1126/science.adl6173
20228  Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.  Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y.  Cancer Med  2021    PubMed ID: 34245137   DOI: 10.1002/cam4.4121
20122  Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R.  Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.  Front Immunol  2020  11:630139  PubMed ID: 33692777   DOI: 10.3389/fimmu.2020.630139
3737  Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.  Cells  2019  8(9):1026  PubMed ID: 31484399   DOI: 10.3390/cells8091026
10759  Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549   DOI: 10.1093/jjco/hyy011
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612   DOI: 10.1002/mc.22671
3727  Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM  K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Mol Oncol  2017  11(9):1130-1142  PubMed ID: 28544747   DOI: 10.1002/1878-0261.12078
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14528  Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.  Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree  PLoS One  2017  12(4):e0175355  PubMed ID: 28388653   DOI: 10.1371/journal.pone.0175355
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123   DOI: 10.1158/2159-8290.CD-15-1442
7256  Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T.  Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.  Int. J. Oncol.  2015  47:1293-302  PubMed ID: 26252371   DOI: 10.3892/ijo.2015.3118
3736  Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.  Mol Cancer Ther.  2015  14(9):1985-93  PubMed ID: 26141945   DOI: 10.1158/1535-7163.MCT-15-0069
10985  Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H.  Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma  Sci Rep  2015  5:16280  PubMed ID: 26538233   DOI: 10.1038/srep16280
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196   DOI: 10.1111/hepr.12312
13689  Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T.  Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma  Jpn J Clin Oncol  2014  44(6):570-8  PubMed ID: 24755544   DOI: 10.1093/jjco/hyu045
14930  Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.  Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater  Int J Oncol  2014  44(4):1139-45  PubMed ID: 24481592   DOI: 10.3892/ijo.2014.2282
18721  Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T.  Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma  J Proteomics  2012  75(5):1577-89  PubMed ID: 22155129   DOI: 10.1016/j.jprot.2011.11.030
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563   DOI: 10.1111/j.1349-7006.2011.02138.x
7767  Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.  Br. J. Cancer  2011  105:131-8  PubMed ID: 21673683   DOI: 10.1038/bjc.2011.199
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941   DOI: 10.1007/s00534-011-0376-7
13667  Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T.  Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment  Cancer Sci  2010  101(4):882-8  PubMed ID: 20088962   DOI: 10.1111/j.1349-7006.2009.01462.x
18737  Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues  J Proteome Res  2009  8(8):4092-103  PubMed ID: 19569727   DOI: 10.1021/pr900468k
3705  Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y.  Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.  World J Gastroenterol  2009  15(31):3865-73  PubMed ID: 19701966   DOI: 10.3748/wjg.15.3865
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
18693  Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S.  Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer  Gastroenterology  2008  135(4):1358-1368  PubMed ID: 18692501   DOI: 10.1053/j.gastro.2008.06.082



Back Back Return Top Page